Protalix BioTherapeutics, Inc. 8-K

What Happened
Protalix BioTherapeutics, Inc. (PLX) announced its financial results for the fiscal year ended December 31, 2025 and provided a business and clinical update in a press release dated March 18, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8-K (Item 2.02), which reports results of operations and financial condition.

Key Details

• Filing date: March 18, 2026; reporting period: fiscal year ended December 31, 2025.
• The press release containing the company's earnings/revenue and clinical program updates was furnished as Exhibit 99.1 to the 8-K.
• The Company noted the Form 8-K information (including Exhibit 99.1) is furnished under General Instruction B.2 of Form 8-K and therefore not “filed” for Section 18 liability or automatically incorporated by reference.
• The report was signed by Dror Bashan, President and Chief Executive Officer.

Why It Matters
This filing provides retail investors with the company’s latest full-year financial results (earnings, revenue and operating results) and an update on business and clinical progress, which are key inputs for evaluating Protalix’s near-term prospects. Investors should read the March 18, 2026 press release (Exhibit 99.1) for the specific revenue, net income/loss, cash position and any commentary on clinical milestones or upcoming catalysts that could affect the stock.